Elite Pharmaceuticals Reports Q2 Revenue Growth and Net Income of $17.3 Million
Elite Pharmaceuticals (ELTP) has announced its financial results for the second quarter ending September 30, 2026. The company reported consolidated revenues of $40.1 million, representing a 10.4% increase compared to the same period in the previous fiscal year. In addition to revenue growth, the company achieved a net income attributable to common shareholders of $17.3 million for the quarter. This performance reflects a significant upward trend in the company's top-line results and profitability over the twelve-month period.